MX392199B - Composiciones farmaceuticas para terapia de combinacion - Google Patents

Composiciones farmaceuticas para terapia de combinacion

Info

Publication number
MX392199B
MX392199B MX2019008917A MX2019008917A MX392199B MX 392199 B MX392199 B MX 392199B MX 2019008917 A MX2019008917 A MX 2019008917A MX 2019008917 A MX2019008917 A MX 2019008917A MX 392199 B MX392199 B MX 392199B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
combination therapy
therapy
relates
present
Prior art date
Application number
MX2019008917A
Other languages
English (en)
Other versions
MX2019008917A (es
Inventor
Benoît Noel
Carole Belanger
Corinne Foucart
Robert Walczak
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2019008917A publication Critical patent/MX2019008917A/es
Publication of MX392199B publication Critical patent/MX392199B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a un producto de combinación y su uso en terapia.
MX2019008917A 2017-01-27 2018-01-29 Composiciones farmaceuticas para terapia de combinacion MX392199B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17305094 2017-01-27
EP17305268 2017-03-13
EP17190723 2017-09-12
PCT/EP2018/052159 WO2018138352A1 (en) 2017-01-27 2018-01-29 Pharmaceutical compositions for combination therapy

Publications (2)

Publication Number Publication Date
MX2019008917A MX2019008917A (es) 2019-12-09
MX392199B true MX392199B (es) 2025-03-21

Family

ID=61157183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008917A MX392199B (es) 2017-01-27 2018-01-29 Composiciones farmaceuticas para terapia de combinacion

Country Status (16)

Country Link
US (2) US11033534B2 (es)
EP (1) EP3573614B1 (es)
JP (1) JP7224294B2 (es)
KR (1) KR102537043B1 (es)
CN (1) CN110198708B (es)
AU (1) AU2018212614B2 (es)
CA (1) CA3046158A1 (es)
CO (1) CO2019008103A2 (es)
IL (1) IL267703B (es)
MX (1) MX392199B (es)
MY (1) MY203981A (es)
NZ (1) NZ755197A (es)
PH (1) PH12019501301A1 (es)
SG (1) SG11201906041QA (es)
WO (1) WO2018138352A1 (es)
ZA (1) ZA201905510B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513762A (ja) * 2016-04-11 2019-05-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞及び線維症の処置方法
EA201991990A1 (ru) * 2017-02-24 2020-04-07 Женфит Фармацевтические композиции для комбинированной терапии
CN110025621A (zh) * 2019-03-13 2019-07-19 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 替唑尼特和硝唑尼特在制备抗炎药物中的应用
US12208087B2 (en) * 2019-04-09 2025-01-28 Genfit Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
JP2022528727A (ja) * 2019-04-12 2022-06-15 ジェンフィット 酸化ストレスに関連する疾患の治療に使用するためのニタゾキサニド及びチアゾリド
KR102199640B1 (ko) * 2020-01-06 2021-01-07 브렉소젠 주식회사 라니피브라노르를 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포기능 강화용 조성물
JP7337317B2 (ja) * 2019-10-23 2023-09-04 カゴメ株式会社 核内受容体活性化用食品組成物及びその製造方法
AU2020376223A1 (en) * 2019-10-28 2022-06-02 Genfit Combination therapy having antioxydant properties
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2022051323A1 (en) * 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a ppar agonist
CN114044761B (zh) * 2021-02-24 2022-05-17 成都贝诺科成生物科技有限公司 一种新的硝基噻唑衍生物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
CA2636527C (en) * 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
US8785442B2 (en) * 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
CN110152000A (zh) 2011-03-02 2019-08-23 J·深塔格 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物

Also Published As

Publication number Publication date
PH12019501301A1 (en) 2019-12-11
JP7224294B2 (ja) 2023-02-17
US11033534B2 (en) 2021-06-15
MX2019008917A (es) 2019-12-09
ZA201905510B (en) 2023-03-29
CN110198708B (zh) 2022-09-20
BR112019015406A2 (pt) 2020-05-19
JP2020506920A (ja) 2020-03-05
US12053456B2 (en) 2024-08-06
IL267703A (en) 2019-08-29
WO2018138352A1 (en) 2018-08-02
NZ755197A (en) 2025-08-29
SG11201906041QA (en) 2019-08-27
IL267703B (en) 2022-05-01
US20190388398A1 (en) 2019-12-26
EP3573614B1 (en) 2024-11-20
KR102537043B1 (ko) 2023-05-25
US20210275504A1 (en) 2021-09-09
EP3573614A1 (en) 2019-12-04
KR20190108141A (ko) 2019-09-23
MY203981A (en) 2024-07-27
EP3573614C0 (en) 2024-11-20
CO2019008103A2 (es) 2019-08-20
AU2018212614A1 (en) 2019-06-27
AU2018212614B2 (en) 2024-02-01
CN110198708A (zh) 2019-09-03
CA3046158A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
MX2019012534A (es) Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico.
EP4620520A3 (en) Methods and compositions relating to chondrisomes
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
CL2015002897A1 (es) Inhibidores de bace1
MX2018000570A (es) Nuevas isoformas de tripsina y su uso.
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
FR3029915B1 (fr) Tripeptides, compositions les comprenant et utilisations notamment cosmetiques
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
MX2017000862A (es) Formulacion de factor viii.
AR104591A1 (es) Piroglutamato de vortioxetina
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.
NZ717192A (en) Anti-inflammatory tripeptides
AU201811074S (en) Dental matrix device
MX2017004909A (es) Composiciones de triptamina y metodos de uso.
PH12017501979A1 (en) Pharmaceutical compound
HK1247917A1 (zh) 与金属和/或自由基螯合构型有关的邻伯二胺，及其抗羰基和氧化应激的活性，及其用途
EA201991733A1 (ru) Фармацевтические композиции для комбинированной терапии